Vista Pharmaceuticals Fair Value
Vista Pharmaceuticals (VISTAPH) average fair value is ₹48.04 across 3 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, vs a current market price of ₹7.9 (+508.1%), fair value range ₹6.31–₹100.31. Also explore VISTAPH stock price history to track price trends across different timeframes.
Fair Value Analysis Export
VISTAPH Fair Value vs Current Price — Valuation Summary
VISTAPH average fair value, fair value range, price gap and valuation status across 3 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation. See VISTAPH price book multiple to compare market price against book value per share.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
VISTAPH Fair Value Analysis — Data Sources & Coverage
Vista Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit VISTAPH share price screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
VISTAPH vs Healthcare Sector Peers — P/E, P/B & Market Cap
Vista Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Par Drugs & Chemical | PAR | 8.67 | 1.01 | ₹111 |
| Jeena Sikho Lifecare | JSLL | 40.02 | 22.33 | ₹7,891 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Acutaas Chemicals | ACUTAAS | 67.74 | 14.46 | ₹24,846 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.